Research and science related to a minor improvement in hairgrowth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.
PP405 is considered a promisinghair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.
Microneedling with 5% minoxidil improves hairgrowth for hair loss patients. Best protocol: 1.5mm dermaroller weekly for 12 weeks or 0.6mm dermapen every 2 weeks for 12 weeks, skipping topicals for 24 hours.
Creatine may counteract minoxidil's hairgrowth effects by closing potassium ATP channels, potentially leading to hair loss in predisposed individuals. Despite anecdotal reports, there is no conclusive evidence linking creatine to hair loss.
A user is trying 2-deoxy-D-ribose with distilled water for hairgrowth, observing new hair and skin pigmentation changes. Others compare it to Minoxidil, expressing interest and caution about its effectiveness and safety.
Dutasteride is effective for many in reducing hair loss and promoting regrowth, often with fewer side effects than finasteride. Combining it with minoxidil is commonly seen as a successful strategy, though results may take several months.
Microneedling with minoxidil significantly boosts hairgrowth, even for non-responders to minoxidil alone. The routine includes a 1.5mm dermaroller weekly and minoxidil twice daily, with some users adding finasteride and tretinoin.
Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
The conversation discusses the potential positive effects of melatonin on hairgrowth. The original poster plans to try both oral and topical melatonin and is seeking recommendations for a good source.
SCUBE3, a protein linked to hairgrowth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hairgrowth therapy.
Whether topical caffeine can be as effective for hairgrowth as minoxidil and finasteride, with various replies discussing the efficacy of these treatments and criticism of Dr. Huberman's research methods.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hairgrowth and reduce hair follicle sensitivity to DHT.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
The user added melatonin to their 5% minoxidil solution for hairgrowth, using a concentration of 0.0033%, which equates to roughly 2mg for a 60ml bottle. They later reported no significant difference and planned to continue the treatment for a few more months before potentially stopping to observe any changes in shedding.
Comparing two upcoming topical hair loss treatments, Fluridil and Breezula, to determine which is most effective for treating hair loss, taking into consideration factors such as price, side effects, potential for hairgrowth, convenience of application, smell, greasiness, and styling after use.
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
Microneedling may enhance hair regrowth by transferring stem cells to dormant follicles, improving the effects of minoxidil. Users discuss using microneedling with needle lengths around 1.5mm to stimulate hairgrowth.
Low-Level Laser Therapy (LLLT) is seen as a safe and effective method for maintaining hair and promoting regrowth in androgenetic alopecia (AGA) and male pattern baldness (MPB), with devices like the HairMax LaserComb® and iRestore helmet being popular. Some users and professionals are skeptical about its long-term effectiveness and cost.
Microneedling for hair restoration involves daily use of a 0.3 mm device and weekly use of a 0.5 mm device. Combining microneedling with Minoxidil can enhance hairgrowth.
Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Treatments for hair loss, such as topical minoxidil, platelet-rich plasma therapy with or without minoxidil, ketoconazole, non-abative radio frequency, natural products, finasteride and cortexolone 17 alpha propionate. The post evaluates the efficacy and safety of these treatments in various studies.
PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.
A naturally occurring sugar, 2-deoxy-D-ribose, may promote hairgrowth by forming new blood vessels. There is skepticism about its effectiveness and concerns about potential side effects, with some users comparing it to existing treatments like Minoxidil and finasteride.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hair follicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.
The conversation discusses the potential of Sanguisorba Officinalis Root Extract as a treatment for hair loss by inhibiting FGF-5. The user also mentions the product évolis, which is based on this extract but is only available in the US and Australia.
DLQ01, a prostaglandin F2α analog, shows promise for hairgrowth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
Painkillers like Aspirin may reduce Minoxidil's effectiveness by inhibiting the enzyme PGHS-1, which is crucial for hairgrowth. Using NSAIDs that inhibit COX-2 or combining Minoxidil with PGF2/E2 analogues or retinoids may enhance its efficacy.